Autologous cultured chondrocytes - Curis

Drug Profile

Autologous cultured chondrocytes - Curis

Alternative Names: Chondrogel

Latest Information Update: 20 Feb 2003

Price : $50

At a glance

  • Originator Curis
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Stress incontinence; Vesicoureteral reflux

Most Recent Events

  • 30 Apr 2002 Discontinued - Phase-II for Stress incontinence in USA (Injection)
  • 01 Apr 2002 Discontinued - Phase-III for Vesicoureteral reflux in USA (Injection)
  • 28 Mar 2002 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top